Once-daily or twice-daily delivery of inhaled corticosteroids: assessment of the efficacy and of influence of the long term treatment on growth in asthmatic children
Abstract
Background: Inhaled corticosteroids are recommended drugs for asthma treatment. Their growth suppressive potential is well-known. Twice-daily delivery is usually used in children, but poor compliance of such long-term treatment may represent a problem which can be resolved with once-daily regimen. The aim of this prospective study was to asses the efficacy and the influence on growth of long term once-daily administration of inhaled fluticasone propionate (FP) in asthmatic Slovene children under 5 years.
Methods: Children with mild persistent asthma took part in parallel group trial. Their parents recorded asthma symptoms, β 2-agonist usage, and PEF using a form for asthma control on a daily basis for a period of one year. According twice or once-daily treatment they were divided in two groups: group A – children receiving FP 100 μg twice-daily and group B – children receiving FP 200 μg once-daily at bedtime. Mean height of 26 children of the same sex and age from each group and of 26 healthy children (groups A1, B1, C) was observed. Chi-square analysis with Yates’ correction and t-tests were employed for between – group analyses (SPSS software 11.0).
Results: FP given once-daily was as effective and tolerated as the same total dose given twice-daily. PEF, asthma symptoms and bronchodilator use of children from group B were not significantly different from those from group A (p > 0.05). The mean height increase of children receiving FP once-daily was smaller for 0.22 cm than of children receiving FP twice-daily and for 0.98 cm than of healthy children (t = 1.56, p = 0.132; DF: 24).
Conclusions: Once-daily administration of inhaled FP in asthmatic children is safe and as effective as twice-daily administration. The suppressive potential is greater when it is given once-daily.
Downloads
References
Maček V. Diagnoza in diferencialna diagnoza astme. Astma pri otroku. Ljubljana: Klinični center, Pediatrična klinika, Služba za pulmologijo; 2003. p. 39–45.
Šuškovič S. Etiopatogeneza, klinična slika in diagnoza astme. Astma. Golnik: Klinika za pljučne bolezni in alergologijo; 2000. p. 21–32.
Borinc-Beden A, Kopriva S, Maček V. Zdravljenje akutnega poslabšanja astme. Astma pri otroku. Ljubljana: Klinični center, Pediatrična klinika, Služba za pulmologijo; 2003. p. 129–38.
Černelč M. Preventivna zdravila za zdravljenje astme pri otroku. Astma pri otroku. Ljubljana: Klinični center, Pediatrična klinika, Služba za pulmologijo; 2003. p. 95–101.
Von Mutius E. The burden of childhood asthma. Arch Dis Child 2000; 82: 2–5.
Warner JO, Naspitz C. Third international pediatric Consensus statement on the management of childhood asthma. Pediatr Pulm 1998; 25: 1–17.
Campbell LM. Once daily inhaled corticosteroids in mild to moderate asthma: Improving acceptance of treatment. Drugs 1999; 58: 25–33.
Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003. Dosegljivo na: http:// bmj.com/cgi/content/full/326/7390/621
Jonasson G, Carlsen KH, Sodal A, Jonasson C, Mowinckel P. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. Eur Respir J 1999; 14: 150–4.
Sherman J, Hutson A, Baumestein S, Hendeles L. Telephoning the patient’s pharmacy to assess adherence with asthma medications by measuring refill rate for prescriptions. J Pediatr 2000; 136: 532–6.
ZuWallack R, Adelglass J, Cliford DP, Duke SP, Wire PD, Faris M, Harding SM. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000; 118: 303–12.
Hodges I, Netherway T. Once-daily inhaled fluticasone propionate is as effective as twice-daily in children with stable mild to moderate asthma. Thorax 1998; 53 Suppl 4: A55.
Nathan RA, Li JTC, Finn A, Jones R, Payne JE, Wolford JP, Harding SM. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118: 296–302.
Wolfe J, Rooklin A, Grady J, Munk ZM, Stevens A, Prillaman B, Duke S, Harding S. Comparison of once and twice daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol 2000; 105: 1153–61.
Hasegawa T, Tomii K, Kikumoto N, Sakamoto H, Maekawa T, Katayama S, et al. Effect of fluticasone propionate at half dose of beclomethasone dipropionate divided twice daily and once daily in asthmatics inhaling beclomethasone 800 micrograms daily or more. Arerugi-Japanese Journal of Allergology 2001; 50: 379–84.
Moller C, Stromberg L, Oldaeus G, Arwestrom E, Kjellman M. Efficacy of once daily administration by turbuhaler in children with stable asthma. Pediatr Pulmonol 1999; 28: 337–43.
Wolthers OD, Heuck C. Assessment of the relation between short and intermediate term growth in children with asthma treated with inhaled glucocorticoids. Allergy 2004; 59: 1193–7.
Brand PLP. Inhaled corticosteroids reduce growth. Or do they? Eur Respir J 2001; 17: 287–94
Heuck C, Wolters OD, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 μg) on growth and collagen turnover in children with asthma: a double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133: 608–12.
The Childhood Asthma Management Program Research Group. Long term effects of budesonide and nedocromil in children with asthma. N Engl J Med 2000; 343: 1054–63.
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343: 1064–9.
Dubus JC, Anhoj J. A review of once-daily delivery of antiasthmatic drugs in children. Pediatr Allergy Immunol 2003; 14: 4–9.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
